Multiple sclerosis (MS)

· SICS Editore
eBook
44
āļŦāļ™āđ‰āļē
āļĄāļĩāļŠāļīāļ—āļ˜āļīāđŒ
āļ„āļ°āđāļ™āļ™āđāļĨāļ°āļĢāļĩāļ§āļīāļ§āđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļāļēāļĢāļ•āļĢāļ§āļˆāļŠāļ­āļšāļĒāļ·āļ™āļĒāļąāļ™ Â āļ”āļđāļ‚āđ‰āļ­āļĄāļđāļĨāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

āđ€āļāļĩāđˆāļĒāļ§āļāļąāļš eBook āđ€āļĨāđˆāļĄāļ™āļĩāđ‰

Multiple sclerosis (MS) is an autoimmune disease of unknown aetiology that affects the white matter of the central nervous system (CNS). The symptoms of multiple sclerosis are diverse, depending on the location and size of the CNS inflammatory lesions (plaques). MS is divided into subtypes: relapsing-remitting, secondary progressive and primary progressive. The relapsing-remitting form is the most common. MS is diagnosed on the basis of clinical presentation, cerebrospinal fluid (CSF) examination and magnetic resonance imaging (MRI). Pulse corticosteroid therapy is used to manage acute exacerbations. The first-line disease-modifying agents indicated for long-term therapy are interferon beta and glatiramer acetate. Natalizumab or fingolimod are used in particularly aggressive disease forms. No curative therapy exists as yet. Disease progress is individual. According to current estimations, MS decreases the patient's life expectancy by about 7 years.

āđƒāļŦāđ‰āļ„āļ°āđāļ™āļ™ eBook āļ™āļĩāđ‰

āđāļŠāļ”āļ‡āļ„āļ§āļēāļĄāđ€āļŦāđ‡āļ™āļ‚āļ­āļ‡āļ„āļļāļ“āđƒāļŦāđ‰āđ€āļĢāļēāļĢāļąāļšāļĢāļđāđ‰

āļ‚āđ‰āļ­āļĄāļđāļĨāđƒāļ™āļāļēāļĢāļ­āđˆāļēāļ™

āļŠāļĄāļēāļĢāđŒāļ—āđ‚āļŸāļ™āđāļĨāļ°āđāļ—āđ‡āļšāđ€āļĨāđ‡āļ•
āļ•āļīāļ”āļ•āļąāđ‰āļ‡āđāļ­āļ› Google Play Books āļŠāļģāļŦāļĢāļąāļš Android āđāļĨāļ° iPad/iPhone āđāļ­āļ›āļˆāļ°āļ‹āļīāļ‡āļ„āđŒāđ‚āļ”āļĒāļ­āļąāļ•āđ‚āļ™āļĄāļąāļ•āļīāļāļąāļšāļšāļąāļāļŠāļĩāļ‚āļ­āļ‡āļ„āļļāļ“ āđāļĨāļ°āļŠāđˆāļ§āļĒāđƒāļŦāđ‰āļ„āļļāļ“āļ­āđˆāļēāļ™āđāļšāļšāļ­āļ­āļ™āđ„āļĨāļ™āđŒāļŦāļĢāļ·āļ­āļ­āļ­āļŸāđ„āļĨāļ™āđŒāđ„āļ”āđ‰āļ—āļļāļāļ—āļĩāđˆ
āđāļĨāđ‡āļ›āļ—āđ‡āļ­āļ›āđāļĨāļ°āļ„āļ­āļĄāļžāļīāļ§āđ€āļ•āļ­āļĢāđŒ
āļ„āļļāļ“āļŸāļąāļ‡āļŦāļ™āļąāļ‡āļŠāļ·āļ­āđ€āļŠāļĩāļĒāļ‡āļ—āļĩāđˆāļ‹āļ·āđ‰āļ­āļˆāļēāļ Google Play āđ‚āļ”āļĒāđƒāļŠāđ‰āđ€āļ§āđ‡āļšāđ€āļšāļĢāļēāļ§āđŒāđ€āļ‹āļ­āļĢāđŒāđƒāļ™āļ„āļ­āļĄāļžāļīāļ§āđ€āļ•āļ­āļĢāđŒāđ„āļ”āđ‰
eReader āđāļĨāļ°āļ­āļļāļ›āļāļĢāļ“āđŒāļ­āļ·āđˆāļ™āđ†
āļŦāļēāļāļ•āđ‰āļ­āļ‡āļāļēāļĢāļ­āđˆāļēāļ™āļšāļ™āļ­āļļāļ›āļāļĢāļ“āđŒ e-ink āđ€āļŠāđˆāļ™ Kobo eReader āļ„āļļāļ“āļˆāļ°āļ•āđ‰āļ­āļ‡āļ”āļēāļ§āļ™āđŒāđ‚āļŦāļĨāļ”āđāļĨāļ°āđ‚āļ­āļ™āđ„āļŸāļĨāđŒāđ„āļ›āļĒāļąāļ‡āļ­āļļāļ›āļāļĢāļ“āđŒāļ‚āļ­āļ‡āļ„āļļāļ“ āđ‚āļ›āļĢāļ”āļ—āļģāļ•āļēāļĄāļ§āļīāļ˜āļĩāļāļēāļĢāļ­āļĒāđˆāļēāļ‡āļĨāļ°āđ€āļ­āļĩāļĒāļ”āđƒāļ™āļĻāļđāļ™āļĒāđŒāļŠāđˆāļ§āļĒāđ€āļŦāļĨāļ·āļ­āđ€āļžāļ·āđˆāļ­āđ‚āļ­āļ™āđ„āļŸāļĨāđŒāđ„āļ›āļĒāļąāļ‡ eReader āļ—āļĩāđˆāļĢāļ­āļ‡āļĢāļąāļš